Biogen outlines Apellis deal impacts with $120M-$130M 2026 other income headwind and non-GAAP EPS accretion in 2027 (NASDAQ:BIIB)
生化基因生化基因(US:BIIB) Seeking Alpha·2026-04-30 02:23

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Biogen outlines Apellis deal impacts with $120M-$130M 2026 other income headwind and non-GAAP EPS accretion in 2027 (NASDAQ:BIIB) - Reportify